El-Far M, Salah N, Essam A, Abd El-Azim A, Karam M, El-Sherbiny IM. Potential anticancer activity and mechanism of action of nanoformulated curcumin in experimental Ehrlich ascites carcinoma-bearing animals.
Nanomedicine (Lond) 2019;
14:553-573. [PMID:
30810086 DOI:
10.2217/nnm-2018-0298]
[Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
AIM
To study the potential use of nanoformulations of curcumin (CUR); CUR-loaded pluronic nanomicelles (CURnp1), and CUR-loaded poly(lactic-co-glycolic acid) nanoparticles (CURnp2) as antitumor agents in Ehrlich ascites carcinoma-bearing animals, and their mechanism of action.
MATERIALS & METHODS
CURnp1 and CURnp2 were prepared, characterized and tested against Ehrlich ascites carcinoma-bearing mice. Superoxide dismutase, catalase (CAT), glutathione, malondialdehyde, histopathological, immunohistochemical studies, cell cycle and caspase-3 were investigated.
RESULTS & CONCLUSION
CURnp1 destroyed tumors via increasing superoxide dismutase, CAT and glutathione, decreasing malondialdehyde through inducing apoptosis by decreasing Ki-67 and Bcl2 expression and activating caspase-3 leading to inhibition of proliferation and cell cycle arrest with progression at G1/S phase. The study demonstrated for the first time superiority of CURnp1 over native CUR and CURnp2 as anticancer agents.
Collapse